M1 Kliniken AG publishes Q1 figures 2023: Strong growth and disproportionate increase in operating result

EQS-News: M1 Kliniken AG / Key word(s): Quarterly / Interim Statement
M1 Kliniken AG publishes Q1 figures 2023: Strong growth and disproportionate increase in operating result
31.05.2023 / 16:52 CET/CEST
The issuer is solely responsible for the content of this announcement.

M1 Kliniken AG publishes Q1 figures 2023:

Strong growth and disproportionate increase in operating result. 
 

• Group revenue rises by 21% to EUR 76.8 million
• Group EBITDA amounts to EUR 5.3 million (previous year: EUR 4.2 million);
  EBIT amounts to EUR 4.0 million (previous year: EUR 2.8 million)
• Beauty segment: sales increase of more than 50% to EUR 20.9 million and EBIT margin above 17% for the first time

Berlin, 31 May 2023 - M1 Kliniken AG (ISIN: DE000A0STSQ8) announces figures for the first quarter of 2023. Accordingly, the consolidated group revenue of the M1 Group increased by around 21% to EUR 76.8 million in the first quarter (previous year: EUR 63.5 million).

Consolidated EBITDA of the M1 Group totalled EUR 5.3 million in Q1 2023 (previous year: EUR 4.2 million), an increase of around 26%. Group EBIT increased by 44% to EUR 4.0 million (previous year: EUR 2.8 million). The Group EBIT margin increased from 4.4% to 5.3%. 

Sales and EBIT in the Beauty segment increased disproportionately in the first quarter of 2023. Sales increased by 51.7% from EUR 13.8 million to EUR 20.9 million. EBIT improved from EUR 1.7 million to EUR 3.6 million. The EBIT margin increased from 12.3% to 17.3%.

The Beauty segment in the home market of Germany achieved sales of EUR 18.1 million and EBIT of EUR 4.1 million (Q1-2022: EUR 2.1 million). The EBIT margin in Germany thus amounted to 22.6%. The international beauty markets posted sales of EUR 2.8 million and EBIT of EUR -0.5 million (Q1 2022: EUR -0.4 million).

With the opening of the 55th medical centre in Sofia/Bulgaria in May 2023, the Eastern European strategy was successfully continued. As a result, the M1 Group is now represented in nine countries.

"Our expansion activities are fully on track and we expect to be able to open five more new locations in the current financial year. The focus is on the international national markets. The importance of foreign locations will increase considerably in the future. To this end, the Group is investing in brand awareness and reach in the country markets served," says the CEO of M1 Kliniken AG, Attila Strauss.

The company's Annual General Meeting scheduled for 19 July 2023 will again be held in person.

About M1 Kliniken AG

M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group of companies offers products and services with the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at more than 50 specialist centres. The M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been pushing ahead with its internationalisation and is currently represented in nine countries. With its stake in HAEMATO AG, M1 Kliniken AG is also in a position to exploit sales and earnings potential of treatment products in the medical-aesthetic field.

31.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com